An organic borane complex contains, as a component, triarylborane having an enhanced bonding between a boron atom and a carbon atom on an aryl group. The organic borane complex contains, as a component, triarylborane having a structure represented by the following general formula (1), wherein X1 and X2 each independently represent an oxygen atom or a sulfur atom; X3 and X4 each independently represent a hydrogen atom or a substituent, or X3 and X4 are linked together to be a single atom; R1 to R3 each independently represent a hydrogen atom or a substituent; and p, q and r each independently represent an integer of 1 to 3. Also disclosed are a composition containing organic borane, and an organic electroluminescent element.

A material, article, system and method include a probe composition that includes a hydrophobic portion, a hydrophilic portion, an analyte-binding portion and a fluorophore portion. The analyte-binding portion is configured to bind to an analyte in an aqueous solution. The fluorophore portion is configured to change an optical property of fluorescent light emitted in response to incident excitation light when the probe composition changes between a first state in which the analyte is not bound to the analyte-binding portion and a second state in which the analyte binds to the analyte-binding portion. A material includes the probe composition and a silicone hydrogel substrate having a hydrogel network that allows flow of aqueous solution through the solution and a silicone network that occupies interstices of the hydrogel network. A contact lens having the material enables remote detection of glucose concentration in tear fluid of a subject.

Provided herein according to some embodiments of the invention are aryl boronate and/or aryl diaminoboryl compounds. Also provided are methods of detecting the presence of hydrogen peroxide (H.sub.2O.sub.2) and/or other reactive oxygen species (ROS) in a cell and/or tissue by contacting the cell and/or tissue with aryl boronate and/or aryl diaminoboryl compounds. Also provided according to embodiments of the invention are methods of producing persulfides in the presence of hydrogen peroxide (H.sub.2O.sub.2) and/or other reactive oxygen species (ROS) in a cell and/or tissue by contacting the cell and/or tissue with aryl boronate and/or aryl diaminoboryl compounds.

Provided herein according to some embodiments of the invention are aryl boronate and/or aryl diaminoboryl compounds. Also provided are methods of detecting the presence of hydrogen peroxide (H.sub.2O.sub.2) and/or other reactive oxygen species (ROS) in a cell and/or tissue by contacting the cell and/or tissue with aryl boronate and/or aryl diaminoboryl compounds. Also provided according to embodiments of the invention are methods of producing persulfides in the presence of hydrogen peroxide (H.sub.2O.sub.2) and/or other reactive oxygen species (ROS) in a cell and/or tissue by contacting the cell and/or tissue with aryl boronate and/or aryl diaminoboryl compounds.

The present invention concerns a compound of formula (I):

##STR00001##

or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.

Described herein are boron-containing compounds, compositions, and methods for their preparation.

Provided are a heterocyclic compound and an organic light-emitting device including the same. The heterocyclic compound includes a fluoro-containing cyclic group. The heterocyclic compound does not include a carbazole group, a dibenzofuran group, a dibenzothiophene group, and/or a triphenylene group. The organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer between the first electrode and the second electrode and including an organic layer, the organic layer including an emission layer and at least one of the heterocyclic compound.

A light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode. The emission layer may include a first compound represented by Formula 1, and at least one of a second compound, a third compound, and a fourth compound. The light emitting element including the first compound represented by Formula 1 exhibits high efficiency and a long lifespan.

##STR00001##

The present invention relates to boron containing compounds of Formula (IA): ##STR00001##
that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

A light emitting element that includes a first electrode, a second electrode facing the first electrode, and an emission layer between the first electrode and the second electrode is provided. The emission layer includes a polycyclic compound represented by Formula 1. The light emitting element has a reduced driving voltage and an increased efficiency.

##STR00001##